Rostafuroxin

DRUG3 trials

Sponsors

sigma-tau i.f.r. S.p.A., RostaQuo S.p.A., Windtree Therapeutics

Conditions

Essential HypertensionHypertension

Phase 2

Efficacy of Rostafuroxin in the Treatment of Essential Hypertension

CompletedNCT00415038

sigma-tau i.f.r. S.p.A.Essential Hypertension

Start: 2005-02-28End: 2007-08-31Updated: 2011-06-17

Antihypertensive Effect of Rostafuroxin Compared With Losartan in Hypertensive Patients Bearing Specified Gene Mutations

RostaQuo S.p.A.Essential Hypertension

Start: 2011-05-31End: 2012-12-31Target: 240Updated: 2011-03-23

Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan

CompletedNCT03217825

Windtree TherapeuticsHypertension

Start: 2015-12-31End: 2018-02-08Updated: 2023-02-21

Related Papers

Abstract P118: Antihypertensive Treatment Guided By Genetics: Pearl-ht, The Randomized Proof-of-concept Trial Comparing Rostafuroxin With Losartan

Hypertension2020-09-01

Main results of the ouabain and adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin.

2011-01-1423 citations